These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30808393)

  • 21. Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.
    Bustad HJ; Kallio JP; Vorland M; Fiorentino V; Sandberg S; Schmitt C; Aarsand AK; Martinez A
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
    Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
    J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for an ancestral founder of the common R116W mutation in the hydroxymethylbilane synthase gene in acute intermittent porphyria in The Netherlands.
    de Rooij FW; Kavelaars FG; Koole-Lesuis H; Wilson JH
    Cell Mol Biol (Noisy-le-grand); 2009 Jul; 55(2):64-9. PubMed ID: 19656453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France.
    Nordmann Y; Puy H; Da Silva V; Simonin S; Robreau AM; Bonaiti C; Phung LN; Deybach JC
    J Intern Med; 1997 Sep; 242(3):213-7. PubMed ID: 9350165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W. A population-based study.
    Andersson C; Floderus Y; Wikberg A; Lithner F
    Scand J Clin Lab Invest; 2000 Nov; 60(7):643-8. PubMed ID: 11202057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating fluorocytes at the first attack of acute intermittent porphyria: a missing link in the pathogenesis.
    Lam CW; Lau KC; Mak CM; Tsang MW; Chan YW
    Clin Chim Acta; 2011 Jan; 412(1-2):208-12. PubMed ID: 20850424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study.
    Bylesjö I; Wikberg A; Andersson C
    Scand J Clin Lab Invest; 2009; 69(5):612-8. PubMed ID: 19401933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the hepatic transcriptome following phenobarbital induction in mice with AIP.
    Chen B; Wang M; Gan L; Zhang B; Desnick RJ; Yasuda M
    Mol Genet Metab; 2019 Nov; 128(3):382-390. PubMed ID: 30777612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute intermittent porphyria: mutation analysis and identification of gene carriers in a German kindred by PCR-DGGE analysis.
    Petrides PE
    Skin Pharmacol Appl Skin Physiol; 1998; 11(6):374-80. PubMed ID: 10343207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria.
    Fraunberg MVUZ; Pischik E; Udd L; Kauppinen R
    Medicine (Baltimore); 2005 Jan; 84(1):35-47. PubMed ID: 15643298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel A219P mutation of hydroxymethylbilane synthase identified in a Chinese woman with acute intermittent porphyria and syndrome of inappropriate antidiuretic hormone.
    Li Y; Qu H; Wang H; Deng H; Liu Z
    Ann Hum Genet; 2015 Jul; 79(4):310-2. PubMed ID: 25787008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self-efficacy and self-management strategies in acute intermittent porphyria.
    Hammersland MH; Aarsand AK; Sandberg S; Andersen J
    BMC Health Serv Res; 2019 Jul; 19(1):444. PubMed ID: 31269991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria.
    Szlendak U; Lipniacka A; Bianketti J; Podolak-Dawidziak M; Bykowska K
    Adv Clin Exp Med; 2015; 24(1):63-8. PubMed ID: 25923088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).
    Solis C; Lopez-Echaniz I; Sefarty-Graneda D; Astrin KH; Desnick RJ
    Mol Med; 1999 Oct; 5(10):664-71. PubMed ID: 10602775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria.
    Jiang L; Berraondo P; Jericó D; Guey LT; Sampedro A; Frassetto A; Benenato KE; Burke K; Santamaría E; Alegre M; Pejenaute Á; Kalariya M; Butcher W; Park JS; Zhu X; Sabnis S; Kumarasinghe ES; Salerno T; Kenney M; Lukacs CM; Ávila MA; Martini PGV; Fontanellas A
    Nat Med; 2018 Dec; 24(12):1899-1909. PubMed ID: 30297912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and molecular analysis of 17 novel variants of hydroxymethylbilane synthase in Chinese patients with acute intermittent porphyria.
    Hu Y; Li W; Kang N; Ma L; Teng Q; Mo G; Wu J; Wang X; Bi R; Zhang S
    Clin Genet; 2022 Jan; 101(1):116-121. PubMed ID: 34523126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.